Legacy Of Many Sponsors Complicated Review Of Vanda's Fanapt
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The multiple sponsors of the antipsychotic Fanapt (iloperidone) produced an inconsistent development program followed by a tumultuous and ultimately dramatic review as FDA worked through a succession of issues surrounding clinical trial design and analysis choices.